SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Phase 3

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

Registration Number: NCT01436175

Lead Sponsor: Shire

Brief Summary: This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous double-blind MDD augmentation study using SPD489.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 1570

Inclusion Criteria

Subject has completed 1 of the respective short-term antecedent SPD489 MDD studies and did not experience any clinically significant AEs in the antecedent study that would preclude exposure to SPD489.

Exclusion Criteria

Subject has any current co-morbid Axis I or Axis II psychiatric disorder (including a lifetime history of psychosis) which was not present or recognized at entry into the antecedent study or has a concurrent chronic or acute illness or unstable medical condition that may deteriorate that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SPD489 + Antidepressant	SPD489 (Lisdexamfetamine dimesylate) + Antidepressant	-

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Diastolic Blood Pressure at Week 52	Baseline, Week 52/ET	Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Columbia-Suicide Severity Rating Scale (C-SSRS)	Week 5 up to Week 52/Early Termination(ET)	C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviour during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Change From Baseline in Systolic Blood Pressure at Week 52	Baseline, Week 52/ET	Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Change From Baseline in Pulse Rate at Week 52	Baseline, Week 52/ET	Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

Secondary Outcome Measures

Name	Time	Method
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities	Week 52/ET	Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET	Baseline, Week 52/ET	Designed to evaluate the extent to which illness symptoms impact a participant's life in 3 areas: work, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort	Week 52/ET	Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)	Week 52/ET	Participants who did not have Clinical Global Impressions - Severity of Illness (CGI-S) assessed at Week 8 in the antecedent study should not have had CGI-I assessed in this study and were excluded from the summary of CGI-I. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.
Short Form-12 Health Survey Version 2 (SF-12V2)	Week 52/ET	SF-12V2 is a multi-purpose, 7-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It is expressed by two summary measures (Aggregate Physical and Aggregate Mental) for which values can range from 0 to 100. A higher score is indicative of a better health state.
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility	Week 52/ET	Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care	Week 52/ET	Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression	Week 52/ET	Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale	Week 52/ET	EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. EQ-5D-5L Visual Analog Scale score is numbered from 0 to 100, where a score of 100 is the best health a participant can imagine
Change From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET	Baseline, Week 52/ET	CSFQ-14 is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Amphetamine Cessation Symptom Assessment (ACSA) Total Score	Week 53	ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)	Week 52/ET	QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. The QIDS-SR was only assessed in the SPD489-322 antecedent study. The QIDS-SR total score is calculated as the sum of the highest score on any 1 of Items 1-4, Item 5, the highest score on any 1 of Items 6-9, Items 10-14, the highest score on either Item 15 or 16.
Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)	Week 52/ET	The Q-LES-Q-SF is a 16-item self-report questionnaire which evaluates general participant satisfaction with health, mood, relationships, functioning in daily life, and their treatment. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total raw score (summary scale score) was calculated by summing item scores 1 to 14 (total raw score range: 14 to 70). Item 15 (satisfaction with medication, raw score range: 1 to 5) and Item 16 (overall satisfaction and contentment; raw score range: 1 to 5) were stand-alone items. For reporting, summary scale, Item 15 and Item 16 raw scores were transformed into percentage maximum possible score which ranged from 0 to 100, where higher scores are indicative of greater enjoyment or satisfaction.
PRUQ-MDD - Number of Hours	Week 52/ET	The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many hours do you usually work or would you usually be expected to work (hrs/week); 2. How many hours did you actually work last week; 3. On average, how many hours do you volunteer per week. Number of hours are reported.
Patient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD)	Week 52/ET	The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered the following questions: 1. Were you hospitalized in the past month, 2. Do you work for pay, 3. If you missed time at work last week, please note all the reasons why, 4. Would you say that the past week was typical, like the rest of the 3 weeks this month, in terms of your working hours, 5. Do you do volunteer work (VW), and 6. If you do not receive money for your work and do not participate in volunteer work, the reason is. Number of participants with response is reported.
PRUQ-MDD - Number of Days of Resource Utilization	Week 52/ET	The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Number of nights in medical/surgical ward, number of nights in ICU, and number of days a participant received home care in the past month are reported.
PRUQ-MDD - Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed)	Week 52/ET	The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many times did you visit the following healthcare providers in the past month: Family doctor/primary care, Non-physician healthcare practitioner (NPHP), Psychiatrist/Psychologist/Counselor (PPC); 2. How many times did you take one of the tests, mentioned below, during the past month: Blood test, CT Scan, X Ray, Renal function, Thyroid function; and 3. How many times did you visit the hospital emergency room (ER), urgent care facility (UCF) or an after-hours clinic (AHC) in the past month. Number of events (visit to health care provider, visit to hospital facilities, and number of times a test was performed) are reported.
PRUQ-MDD - Effect of Depressive Symptoms	Week 52/ET	The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions on a 0 to 10 point scale - 1. During past week, how much did depressive symptoms affect work productivity; 2. During past week, how much did depressive symptoms affect regular non-work daily activities. Higher scores indicates more effect of depressive symptoms on work productivity and non-work daily activities.

Trial Locations

Locations (207): Medical University of South Carolina, Anxiety Disorders Program
🇺🇸
North Charleston, South Carolina, United States
Future Search Trials of Dallas, LP
🇺🇸
Dallas, Texas, United States
START Clinic for Mood and Anxiety Disorders
🇨🇦
Toronto, Ontario, Canada
Semel Institute for Neuroscience & Human Behavior at UCLA
🇺🇸
Los Angeles, California, United States
Klinika Chorob Psychicznych i Zaburzen Nerwicowych
🇵🇱
Gdansk, Poland
Zespol Opleki Zdrowotnej w Chelmole
🇵🇱
Chelmno, Poland
NZOZ Syntonia
🇵🇱
Kielce, Poland
Affiliated Research Institute
🇺🇸
San Diego, California, United States
PCSD - Feighner Research
🇺🇸
San Diego, California, United States
Sharp Mesa Vista Hospital
🇺🇸
San Diego, California, United States
Davis Clinic
🇺🇸
Indianapolis, Indiana, United States
Clinical Research Consortium
🇺🇸
Las Vegas, Nevada, United States
Community Research, Inc.
🇺🇸
Cincinnati, Ohio, United States
Summit Research Network (Seattle) LLC
🇺🇸
Seattle, Washington, United States
Clinical Trials of Texas, Inc.
🇺🇸
San Antonio, Texas, United States
Psicomed Estudio Medicos
🇨🇱
Antofagasta, Chile
Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia" Sectia Clinica Psihiatrie I
🇷🇴
Bucuresti, Romania
Somerset West Clinical Research Unit
🇿🇦
Somerset West, Western Cape, South Africa
Lorentina 2102 SRL
🇷🇴
Targoviste, Romania
B&B Investigaciones Medicas, SC
🇲🇽
Sinaloa, Mazatian, Mexico
CRI Centro Regiomontano de Investigacion Clinica S.C
🇲🇽
Nuevo Leon, Monterrey, Mexico
Clinical Innovation, Inc.
🇺🇸
Costa Mesa, California, United States
Catalina Research Institute, LLC
🇺🇸
Chino, California, United States
Shanti Clinical Trials
🇺🇸
Colton, California, United States
MCB Clinical Research Centers
🇺🇸
Colorado Springs, Colorado, United States
Arkansas Psychiatric Clinical Research Trials, P.A.
🇺🇸
Little Rock, Arkansas, United States
ResearchOne, Inc.
🇺🇸
Scottsdale, Arizona, United States
North County Clinical Research
🇺🇸
Oceanside, California, United States
American Neuropsychiatric Research, Inc.
🇺🇸
Carson, California, United States
South Coast Clinical Trials, Inc.
🇺🇸
Anaheim, California, United States
Anderson Clinical Research
🇺🇸
Redlands, California, United States
ATP Clinical Research
🇺🇸
Costa Mesa, California, United States
UC, Irvine Child Development Center
🇺🇸
Irvine, California, United States
Collaborative Neuroscience Network, Inc.
🇺🇸
Garden Grove, California, United States
Irvine Center For Clinical Research
🇺🇸
Irvine, California, United States
Pacific Research Partners
🇺🇸
Oakland, California, United States
BreakThrough Clinical Trials, LLC
🇺🇸
San Bernardino, California, United States
Caliifornia Neuroscience Research Medical Group
🇺🇸
Sherman Oaks, California, United States
Neuropsychiatric Center of Orange County
🇺🇸
Santa Ana, California, United States
Connecticut Clinical Research
🇺🇸
Cromwell, Connecticut, United States
Institute of Living - Hartford Hospital
🇺🇸
Hartford, Connecticut, United States
CNS Clinical Research Group
🇺🇸
Coral Springs, Florida, United States
Atlanta Institute of Medicine & Research
🇺🇸
Atlanta, Georgia, United States
Carman Research
🇺🇸
Smyrna, Georgia, United States
Alexian Brothers Center for Psychiatric Research
🇺🇸
Hoffman Estates, Illinois, United States
Psyichiatric Medicine Associates, LLC
🇺🇸
Skokie, Illinois, United States
Heartland Research Associates
🇺🇸
Wichita, Kansas, United States
Comprehensive Psyichatric Associates
🇺🇸
Gladstone, Missouri, United States
St. Charles Psychiatric Associates - Midwest Research Group
🇺🇸
Saint Charles, Missouri, United States
Bio Behavioral Health
🇺🇸
Toms River, New Jersey, United States
Ohio State University Department of Psychiatry
🇺🇸
Columbus, Ohio, United States
Belmont Center for Comprehensive Treatment
🇺🇸
Philadelphia, Pennsylvania, United States
Marienthal Psychiatry & Psychology Center of Mustamae
🇪🇪
Tallinn, Estonia
Jaanson & Laane Ou
🇪🇪
Tartu, Estonia
Independent Physician Consultants (dba IPC Research)
🇺🇸
Waukesha, Wisconsin, United States
Psychiatrie Ricany
🇨🇿
Ricany, Praha Vychod, Czechia
Private Practice Drs. Bitter/Schumann
🇩🇪
Bochum, Germany
CRI Worldwide LLC
🇺🇸
Philadelphia, Pennsylvania, United States
Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc.
🇨🇦
Vancouver, British Columbia, Canada
Research Strategies of Memphis, LLC
🇺🇸
Memphis, Tennessee, United States
Bay Area Clinical Services
🇺🇸
Friendswood, Texas, United States
Wharton Research Center, Inc.
🇺🇸
Wharton, Texas, United States
Anxiety and Mood Disorder Center
🇨🇦
Mississauga, Ontario, Canada
Grayline Clinical Drug Trials
🇺🇸
Wichita Falls, Texas, United States
Ericksen Research and Development
🇺🇸
Clinton, Utah, United States
Dr. Alexander McIntyre Inc
🇨🇦
Penticton, British Columbia, Canada
Psychiatric Consultants, PC
🇺🇸
Franklin, Tennessee, United States
Biomedica Research Group
🇨🇱
Providencia, Santiego, Chile
Manna Research
🇨🇦
Toronto, Ontario, Canada
Dean Foundation for Health, Research, and Education
🇺🇸
Middleton, Wisconsin, United States
International Sleep Clinic, West Parry Sound Health Centre
🇨🇦
Parry Sound, Ontario, Canada
Tartu University Hospital
🇪🇪
Tartu, Estonia
Medicana s.r.o.
🇨🇿
Horovice, Czechia
Emovis GmbH
🇩🇪
Berlin, Germany
Centro de Estudios Clinicos (CEC)
🇨🇱
Providencia, Santiago, Chile
Supervize s.r.o.
🇨🇿
Kutna Hora, Czechia
Bialbi s.r.o.
🇨🇿
Litomerice, Czechia
Especialidades Medicas L y S
🇨🇱
Las Condes, Santiagio, Chile
North Estonia Medical Centre Foundation
🇪🇪
Tallinn, Estonia
Complete Facharzt fur Neurologie und Psychiatrie
🇩🇪
Berlin, Germany
Clintrial s.r.o.
🇨🇿
Prague 10, Czechia
Satucon Oy / Privater
🇫🇮
Kuopio, Finland
Puutonin Psykiatripalvelu
🇫🇮
Turku, Finland
Semmelweis Egyetem Pszichiatrial es Pszichoterapias Klinkia
🇭🇺
Budapest, Hungary
Spitalui Clinic Judetean Mures
🇷🇴
Targu Mures, Romania
Centrum Psychiatrii i Psychoterapi
🇵🇱
Gorlice, Poland
Hospital Clinico Universitario Lozano Blesa
🇪🇸
Zaragoza, Spain
Birmingham Research Group
🇺🇸
Birmingham, Alabama, United States
SP Research, PPC dba Oklahoma Clinical Research Center
🇺🇸
Oklahoma City, Oklahoma, United States
Dr. Sunny Johnson Medical Corporation, Medican Research Associates
🇨🇦
Mississauga, Ontario, Canada
Sleep & Alertness Clinic
🇨🇦
Toronto, Ontario, Canada
Chatham-Kent Clinical Trials Research Centre
🇨🇦
Chatham, Ontario, Canada
l'Hopital Louis H. Lafontaine
🇨🇦
Montreal, Quebec, Canada
Q & T Research Sherbrooke Inc.
🇨🇦
Sherbrooke, Quebec, Canada
Kells Medical Research Group Inc.
🇨🇦
Pointe Claire, Quebec, Canada
Richmond Behavioral Associates
🇺🇸
Staten Island, New York, United States
Psychiatry Trial, s.r.o
🇨🇿
Prague, Czechia
Diligent Clinical Trials
🇺🇸
Downey, California, United States
A. K. Karan Holdings, Ltd.
🇨🇦
Oakville, Ontario, Canada
Medical Services Prague s.r.o.
🇨🇿
Prague, Czechia
Synergy Clinical Research Center of Escondido
🇺🇸
Escondido, California, United States
Omega Clinical Trials, LLC
🇺🇸
La Habra, California, United States
Pasadena Research Institute, LLC
🇺🇸
Pasadena, California, United States
Artemis Institute for Clinical Research
🇺🇸
San Diego, California, United States
Clinical Innovations, Inc.
🇺🇸
San Diego, California, United States
Florida Clinical Research Center, LLC
🇺🇸
Maitland, Florida, United States
Geriatric and Adult Psychiatry, LLC
🇺🇸
Hamden, Connecticut, United States
The Hospital of Central Connecticut
🇺🇸
New Britain, Connecticut, United States
Gulfcoast Clinical Research Center
🇺🇸
Fort Myers, Florida, United States
Emerald Coast Mood & Memory, PA
🇺🇸
Fort Walton Beach, Florida, United States
Clinical Neuroscience Solutions, Inc.
🇺🇸
Memphis, Tennessee, United States
Amit Vijapura MD
🇺🇸
Jacksonville, Florida, United States
Suncoast Clinical Research
🇺🇸
New Port Richey, Florida, United States
Meridien Research
🇺🇸
Saint Petersburg, Florida, United States
Fidelity Clinical Research Inc
🇺🇸
North Miami, Florida, United States
Scientific Clinical Research Inc.
🇺🇸
North Miami, Florida, United States
Psychiatric Associates
🇺🇸
Lake City, Florida, United States
Janus Center for Psychiatric Research
🇺🇸
West Palm Beach, Florida, United States
Comprehensive Clinical Development, Inc.
🇺🇸
Fresh Meadows, New York, United States
Kolin Research Group
🇺🇸
Winter Park, Florida, United States
Atlanta Center for Medical Research
🇺🇸
Atlanta, Georgia, United States
Clinical Research of Central Florida
🇺🇸
Winter Haven, Florida, United States
Institute for Behavioral Medicine, LLC
🇺🇸
Smyrna, Georgia, United States
Pedia Research, LLC
🇺🇸
Owensboro, Kentucky, United States
Louisiana Clinical Research LLC
🇺🇸
Shreveport, Louisiana, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Northwest Indiana Center for Clinical Research
🇺🇸
Valparaiso, Indiana, United States
American Medical Research, Inc.
🇺🇸
Oakbrook Terrace, Illinois, United States
Sleep and Behavior Medicine Institute
🇺🇸
Vernon Hills, Illinois, United States
Clinical Trials Technology, Inc.
🇺🇸
Prairie Village, Kansas, United States
MCM Clinical Research LLC
🇺🇸
Florence, Kentucky, United States
Potomac Grove Clinical Research Center
🇺🇸
Gaithersburg, Maryland, United States
Pharmasite Research, Inc.
🇺🇸
Baltimore, Maryland, United States
Adams Clinical Trials, LLC
🇺🇸
Watertown, Massachusetts, United States
Office of Marc Hertzman, MD
🇺🇸
Rockville, Maryland, United States
Private Practice - Howard J. Ilivicky
🇺🇸
O'Fallon, Missouri, United States
Mid-America Clinical Research
🇺🇸
Saint Louis, Missouri, United States
Premier Psychiatric Research Institute
🇺🇸
Lincoln, Nebraska, United States
Center For Emotional Fitness
🇺🇸
Cherry Hill, New Jersey, United States
Mercy Health Research
🇺🇸
Saint Louis, Missouri, United States
CRI Worldwide, LLC
🇺🇸
Willingboro, New Jersey, United States
Albuquerque Neuroscience Inc.
🇺🇸
Albuquerque, New Mexico, United States
Clinilabs, Inc.
🇺🇸
New York, New York, United States
Brooklyn Medical Institutes
🇺🇸
Brooklyn, New York, United States
Bioscience Research LLC
🇺🇸
Mount Kisco, New York, United States
Medical & Behavioral Health Research, PC
🇺🇸
New York, New York, United States
Mount Sinai School of Medicine
🇺🇸
New York, New York, United States
Fieve Clinical Research
🇺🇸
New York, New York, United States
Triangle Neuropsyhiatry
🇺🇸
Durham, North Carolina, United States
Clinical Trials of America
🇺🇸
Hickory, North Carolina, United States
Sleep Medicine Centers of Western New York
🇺🇸
West Seneca, New York, United States
Dr. Richard Weisler
🇺🇸
Raleigh, North Carolina, United States
Neurology & Neuroscience Center of Ohio
🇺🇸
Toledo, Ohio, United States
Northcoast Clinical Trials
🇺🇸
Beachwood, Ohio, United States
North Star Medical Research, LLC
🇺🇸
Middleburg Heights, Ohio, United States
Lindner Center for Hope
🇺🇸
Mason, Ohio, United States
Midwest Clinical Research Center
🇺🇸
Dayton, Ohio, United States
IPS Research Company
🇺🇸
Oklahoma City, Oklahoma, United States
Sooner Clinical Research
🇺🇸
Oklahoma City, Oklahoma, United States
Lehigh Center for Clinical Research
🇺🇸
Allentown, Pennsylvania, United States
Suburban Research Associates
🇺🇸
Media, Pennsylvania, United States
Paramount Clinical Research
🇺🇸
Bridgeville, Pennsylvania, United States
University Services
🇺🇸
West Chester, Pennsylvania, United States
Rhode Island Mood & Memory Research Institute
🇺🇸
East Providence, Rhode Island, United States
UPMC Western Psychiatric Institute and Clinic
🇺🇸
Pittsburgh, Pennsylvania, United States
Clinical Research Associates, Inc.
🇺🇸
Nashville, Tennessee, United States
Pillar Clinical Research, LLC
🇺🇸
Dallas, Texas, United States
KRK Medical Research
🇺🇸
Dallas, Texas, United States
Houston Clinical Trials, LLC
🇺🇸
Houston, Texas, United States
Recherches Neuro-Hippocampe
🇨🇦
Gatineau, Quebec, Canada
Saint Anne s.r.o., Psychiatricka ambulance
🇨🇿
Brno, Czechia
Psychiatricka ambulance
🇨🇿
Brno, Czechia
Gemeinschaftspraxis fur Neurologie und Psychiatrie
🇩🇪
Westerstede, Germany
ARTES Psykiatrinen Palvelukeskus Oy
🇫🇮
Helsinki, Finland
ZSL Zentrum fuer medizinische Studien in Leipzig
🇩🇪
Leipzig, Germany
Facharzt fur Neurologie und Psychiatrie
🇩🇪
Berlin, Germany
Complete Karlstr
🇩🇪
Munchen, Germany
Studienzentrum Klinikum Nuernberg
🇩🇪
Nuernberg, Germany
Medizinisches Studienzentrum Wuerzburg
🇩🇪
Wuerzburg, Germany
Somni bene GmbH
🇩🇪
Schwerin, Germany
Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum
🇭🇺
Debrecen, Hungary
Prywatne Gabinety Lekarskie "Promedicus" Anna Agnieszka Tomczak
🇵🇱
Bialystok, Poland
Centrum Badan Klinicznych PI-House sp. z o. o.
🇵🇱
Gdansk, Poland
Centrum Badan Klinicznych Pl-House
🇵🇱
Gdansk, Poland
Dharma Institute and Research Center
🇵🇷
San Juan, Puerto Rico
INSPIRA Clinical Research
🇵🇷
San Juan, Puerto Rico
Cape Trial Centre
🇿🇦
Bellville, Cape Town, South Africa
Hospital Universitario Infanta Leonor
🇪🇸
Madrid, Spain
Hospital Fundacion de Alcorcon
🇪🇸
Madrid, Spain
Flexivest Fourteen Research Centre
🇿🇦
Cape Town, South Africa
Hospital Universitari de Bellvitge
🇪🇸
Barcelona, Spain
Centro de Salud Mental II la Corredoria
🇪🇸
Oviedo, Spain
Centro de Salud Alamedilla Unidad de Salud Mental
🇪🇸
Salamanca, Spain
Complejo hospitalario de Zamora
🇪🇸
Zamora, Spain
Alliance Research Group
🇺🇸
Richmond, Virginia, United States
Sarkis Clinical Trials
🇺🇸
Gainesville, Florida, United States
Compass Research, LLC
🇺🇸
Orlando, Florida, United States
Ali A. Kashfi, MD, PA
🇺🇸
Orlando, Florida, United States
Stedman Clinical Trials
🇺🇸
Tampa, Florida, United States
Klinika Chorob Psychicznych i Zaburzen Nerwicowych Uniwersyteckie Centrum Kliniczne
🇵🇱
Gdansk, Poland
Samodzieiny Publiczny Zespol Zakladow Opieki Zdrowotnej w Zurominie
🇵🇱
Zuromin, Poland
Summit Research Network (Oregon) Inc.
🇺🇸
Portland, Oregon, United States
Western Affiliated Research Institute
🇺🇸
Denver, Colorado, United States
The Center for Pharmaceutical Research PC
🇺🇸
Kansas City, Missouri, United States
FutureSearch Clinical Trials, LP
🇺🇸
Austin, Texas, United States
Montefiore Medical Center
🇺🇸
Bronx, New York, United States
Thomas Jefferson University
🇺🇸
Philadelphia, Pennsylvania, United States